In vivo effects of vitamin D analogues in animal models of cancer
Tumor, model | Analogue | Dose | Effect | Hypercalcemia | Ref. | |||||
---|---|---|---|---|---|---|---|---|---|---|
Breast | ||||||||||
N-methyl-N′-nitrosourea induced | EB1089 | 1 μg/kg p.o. | Tumor suppression | Marked | (71) | |||||
Ro24-5531 | 1.25 and 2.5 nmol/kg diet | Reduced tumor incidence | None | (78) | ||||||
1α(OH)D5 | 58.4 and 116.8 nmol/kg diet* | Reduced tumor incidence | None | (79) | ||||||
MCF-7 xenografts | 22-Oxa-1α,25(OH)2D3 | 1.0 μg/kg p.o. | Tumor suppression | None | (73) | |||||
TX522 | 80 μg/kg/2 d i.p. | Tumor suppression | None | (77) | ||||||
TX527 | 25 μg/kg/2 d i.p. | Tumor suppression | Marked | (77) | ||||||
MDA-MB-231 xenografts | EB1089 | 14 pmol/L/24 h, infusion | Inhibited skeletal metastasis | None | (72) | |||||
Prostate | ||||||||||
LNCaP xenografts | EB1089 | 0.5 μg/kg i.p. | Tumor suppression | None | (81) | |||||
EB1089 | 1 μg/kg p.o. | Tumor suppression | Mild | (86) | ||||||
LG190119 | 3 and 10 mg/kg p.o. | Tumor suppression | None | (86) | ||||||
LG190119 | 10 mg/kg p.o. | Reduced tumor incidence | None | (86) | ||||||
PC-3 xenografts | Ro23-7553 | 1.6 μg/animal i.p. | Tumor suppression | None | (84) | |||||
MAT LyLu tumors in rats | EB1089 | 0.5 and 1.0 μg/kg i.p. | Inhibited lung metastasis | Marked | (82) | |||||
MDA-PCa 2b xenografts | JK-1626-2 | 4 μg/kg s.c. | Inhibited metastatic bone lesions | None | (83) | |||||
Colon | ||||||||||
1,2-Dimethylhydrazine induced | 22-Oxa-1α,25(OH)2D3 | 30 μg/kg i.p.† | Reduced aberrant crypt foci | None | (91) | |||||
Ro25-5317 | 3.5 nmol/kg diet | Reduced tumor incidence | None | (88) | ||||||
Ro25-9022 | 3.0 and 3.5 nmol/kg diet | Reduced tumor incidence | None | (88) | ||||||
Azoxymethane induced | Ro24-5531 | 2.5 nmol/kg diet | Reduced tumor incidence | None | (89) | |||||
1α(OH)D5 | 58.4 nmol/kg diet | Reduced aberrant crypt foci | None | (79) | ||||||
LoVo xenografts | EB1089 | 0.1 and 0.5 μg/kg p.o. | Tumor suppression | None | (87) | |||||
HT-29 xenografts | Ro25-6760 | 0.1 and 0.2 μg/animal i.p | Tumor suppression | None | (90) | |||||
MC-26 xenografts | RO-4383561 | 0.02 μg E i.p. | Reduced tumor growth | None | (92) |